Mission Statement, Vision, & Core Values (2024) of Day One Biopharmaceuticals, Inc. (DAWN)

An Overview of Day One Biopharmaceuticals, Inc. (DAWN)

General Summary of Day One Biopharmaceuticals, Inc. (DAWN)

Day One Biopharmaceuticals, Inc. (DAWN) was founded with a focus on developing innovative treatments for pediatric patients with cancer. The company is dedicated to transforming the lives of these patients through targeted therapies. As of 2024, Day One has received FDA approval for its leading product, OJEMDA, a treatment for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation. This approval was granted in April 2024, marking a significant milestone in the company’s history.

In addition to OJEMDA, Day One is advancing other product candidates, including tovorafenib, DAY301, and VRK1, which are currently in various stages of clinical development. The company’s commitment to pediatric oncology has established it as a key player in this niche market.

As of 2024, Day One Biopharmaceuticals reported total sales of $28.3 million from OJEMDA in the United States for the nine months ending September 30, 2024.

Company's Financial Performance in the Latest Financial Reports

During the nine months ended September 30, 2024, Day One Biopharmaceuticals achieved a record-breaking total revenue of $101.9 million, a significant increase compared to the previous year. This revenue comprised:

• Product revenue: $28.3 million from OJEMDA
• License revenue: $73.7 million related to the Ipsen License Agreement

The company reported a net loss of $29.8 million for the same period, a marked improvement from a net loss of $134.4 million in the prior year. Total operating expenses for the nine months were $253.9 million, which included:

• Research and Development Expenses: $165.9 million
• Selling, General and Administrative Expenses: $85.7 million

Day One recorded a gain of $108.0 million from the sale of a priority review voucher, further enhancing its financial standing. The company's liquidity is robust, with $558.4 million in cash and cash equivalents as of September 30, 2024, sufficient to meet its capital requirements for at least the next twelve months.

Introduction to Day One Biopharmaceuticals as a Leader in the Industry

Day One Biopharmaceuticals has positioned itself as a leader in the biopharmaceutical industry, particularly in the development of therapies for pediatric cancers. The approval of OJEMDA not only underscores the company’s innovative approach but also its commitment to addressing a critical need within the oncology space. The company’s robust pipeline, combined with its strategic partnerships, enhances its potential for future growth and success.

With a focus on rigorous clinical trials and a commitment to bringing effective treatments to market, Day One is poised for continued success. Investors and stakeholders are encouraged to explore further details regarding the company’s journey and vision for enhancing pediatric cancer treatment.

Mission Statement of Day One Biopharmaceuticals, Inc. (DAWN)

Mission Statement of Day One Biopharmaceuticals, Inc. (DAWN)

Day One Biopharmaceuticals, Inc. is dedicated to addressing the unmet needs in pediatric cancer treatment. The company focuses on pioneering innovative therapies aimed at improving the lives of patients diagnosed with cancer, particularly children. This mission is encapsulated in their commitment to re-envision drug development from the very first day of a patient’s journey. The significance of this mission statement lies in its role as a guiding principle for the company’s strategic objectives, ensuring that all initiatives align with their core purpose of enhancing patient outcomes through groundbreaking therapies.

Core Component 1: Innovation

At the heart of Day One's mission is a strong emphasis on innovation. The company strives to develop novel therapeutics that can significantly improve treatment outcomes for pediatric patients. A prime example of this commitment is the FDA approval of OJEMDA (tovorafenib) in April 2024, designed for treating patients with relapsed or refractory pediatric low-grade glioma (pLGG). This approval was granted under the accelerated approval pathway, based on the drug's demonstrated efficacy in clinical trials, which showed a rapid response rate and durable outcomes in patients with specific genetic mutations.

Financially, the approval of OJEMDA has positioned Day One to generate substantial revenue, with net product revenue reported at $28.3 million for the nine months ended September 30, 2024. This revenue reflects the successful commercialization of their innovative product, showcasing how a focus on innovation can translate into tangible financial success.

Core Component 2: Patient-Centric Approach

Day One's mission emphasizes a patient-centric approach, ensuring that the needs and experiences of patients are at the forefront of their operations. This commitment is evident in the company’s strategic decision to focus on pediatric cancers, which historically have seen limited therapeutic advancements. By prioritizing this demographic, Day One aims to fill significant gaps in treatment options available to younger patients.

The company’s efforts to maintain a patient-focused philosophy are reflected in their operational metrics. For instance, as of September 30, 2024, Day One reported a net loss of $29.8 million, which was primarily due to continued investment in research and development to further its mission. This investment underscores the company's dedication to developing therapies that address critical patient needs, rather than solely focusing on short-term profitability.

Core Component 3: Commitment to Quality

The third core component of Day One's mission statement is a commitment to quality in all aspects of their operations, from research and development to patient care. The company adheres to rigorous standards in clinical trials and product development to ensure that their therapies are safe and effective. This commitment is vital for maintaining trust with healthcare providers, patients, and regulatory bodies.

As evidence of this commitment, Day One has made significant financial investments in quality assurance processes. For the nine months ended September 30, 2024, research and development expenses totaled $165.9 million, reflecting the company’s focus on maintaining high standards in product development. This dedication not only supports the efficacy of their treatments but also enhances the overall reputation of the company in the biopharmaceutical industry.

This table summarizes key financial metrics for Day One Biopharmaceuticals, underscoring the company's financial trajectory and its alignment with the mission components of innovation, patient-centricity, and quality commitment.

Vision Statement of Day One Biopharmaceuticals, Inc. (DAWN)

Vision Statement Components of Day One Biopharmaceuticals, Inc. (DAWN)

The vision statement of Day One Biopharmaceuticals, Inc. (DAWN) focuses on transforming the treatment landscape for pediatric patients with cancer. The company's commitment is to develop innovative therapies that significantly impact the lives of patients and their families.

Day One Biopharmaceuticals aims to lead in the development of innovative therapeutics specifically for pediatric oncology. As of 2024, the company has made significant strides in this area, particularly with the FDA approval of OJEMDA, a treatment for patients with relapsed or refractory pediatric low-grade glioma (pLGG) harboring BRAF mutations. This approval was granted on April 23, 2024, marking a pivotal moment in the company's journey towards fulfilling its vision of providing groundbreaking treatments for children with cancer.

The company emphasizes a patient-centric approach in all aspects of its operations. This vision is reflected in its research and development strategy, which prioritizes the needs of pediatric patients. Day One Biopharmaceuticals has committed to addressing the unique challenges faced by this vulnerable population, ensuring that their therapies are not only effective but also safe and tolerable for young patients.

In 2024, Day One Biopharmaceuticals reported a substantial increase in research and development expenses, amounting to $165.9 million for the nine months ended September 30, 2024, compared to $93.2 million for the same period in 2023. This reflects a 78% increase, underscoring the company's dedication to advancing its therapeutic pipeline and fulfilling its vision of innovative treatment solutions for pediatric cancers.

Day One Biopharmaceuticals recognizes the importance of collaboration in achieving its vision. The company has engaged in strategic partnerships, including a recent agreement with Ipsen, which provided an upfront license fee of $70.8 million and a concurrent investment of $40.0 million in common stock. These collaborations enhance the company's capacity to innovate and expand its reach in developing treatments for pediatric cancers.

With an accumulated deficit of $488.4 million as of September 30, 2024, Day One Biopharmaceuticals continues to focus on long-term growth and sustainability. The company holds $558.4 million in cash and cash equivalents, which it believes will be sufficient to support its operations for at least the next twelve months. This financial stability is crucial for driving the vision forward and ensuring that the company can meet its goals in pediatric oncology.

Core Values of Day One Biopharmaceuticals, Inc. (DAWN)

Core Value: Commitment to Patients

The core value of commitment to patients is fundamental to Day One Biopharmaceuticals, Inc. (DAWN). This value underlines the company's dedication to developing innovative therapies for pediatric cancer, particularly in areas of unmet medical need.

Day One Biopharmaceuticals demonstrated this commitment through the FDA approval of its lead product, OJEMDA, in April 2024. This product is aimed at treating patients aged six months and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring BRAF mutations. The approval marks a significant milestone, as it provides a new treatment option for a patient population that has historically faced limited therapeutic choices.

Core Value: Innovation

Innovation is a core value that drives Day One's research and development strategies. The company focuses on pioneering new treatments that push the boundaries of current medical practices.

In 2024, Day One entered into various licensing agreements, including a notable one with Ipsen Pharma for the commercialization of tovorafenib outside the U.S., which included an upfront payment of $70.8 million. Additionally, the company is actively advancing its pipeline, which includes DAY301, currently in clinical trials, emphasizing its commitment to innovative cancer therapies.

Core Value: Collaboration

Collaboration stands as a vital core value for Day One Biopharmaceuticals, facilitating partnerships that enhance its research capabilities and accelerate drug development.

For example, Day One's collaboration with Viracta resulted in a $9.0 million milestone payment in May 2024, demonstrating the effectiveness of strategic partnerships. Furthermore, the company has established several licensing agreements, such as the one with MabCare Therapeutics, which grants them rights to develop and commercialize new therapeutic options.

Core Value: Integrity

Integrity is integral to Day One's operations and interactions with stakeholders. The company maintains transparency in its clinical trials and regulatory submissions.

Day One's financial disclosures reflect its commitment to integrity, noting an accumulated deficit of $488.4 million as of September 30, 2024, while also reporting a net income of $37.0 million for the quarter ended September 30, 2024. Such transparency in financial reporting fosters trust with investors and the broader community.

Core Value: Excellence

Excellence is a core value that influences the operational standards and quality of work at Day One Biopharmaceuticals. The company strives for the highest quality in its research and product development processes.

In its recent financial report, Day One highlighted significant investments in research and development, totaling approximately $165.9 million for the nine months ended September 30, 2024. This substantial investment underscores the company's dedication to excellence in bringing innovative therapies to market.

Article updated on 8 Nov 2024

Resources:

• Day One Biopharmaceuticals, Inc. (DAWN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Day One Biopharmaceuticals, Inc. (DAWN)' financial performance, including balance sheets, income statements, and cash flow statements.
• SEC Filings – View Day One Biopharmaceuticals, Inc. (DAWN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.